Amgens Otezla bags expanded FDA nod in psoriasis; I-Mab CEO hits the exit amid shakeup at Chinese firm

Just a few weeks after Otezla notched a Phase III win and hit all primary and secondary endpoints for a trial in genital psoriasis, Amgen